ASX:MDCMedlab Clinical Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Medlab Clinical Limited Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$0.22 -0.01 (-4.44 %) (As of 05/13/2020) Add Compare Share Today's RangeA$0.22Now: A$0.22▼A$0.2250-Day RangeA$0.22MA: A$0.21▼A$0.2252-Week RangeA$0.13Now: A$0.22▼A$0.55Volume36,677 shsAverage VolumeN/AMarket Capitalization$50.14 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlinesOptions Chain Medlab Clinical Limited, a medical research and development facility, engages in nutraceutical products and pharmaceutical research businesses in Australia. The company develops bio-therapeutics for chronic kidney diseases, pre-diabetes/obesity, depression, musculoskeletal muscle loss associated with ageing, and non-opioid pain management. It also provides nutraceuticals for anti-inflammatory, cardiovascular support, endocrine support, gastrointestinal support, immunological support, infants and toddlers, metabolic support, musculoskeletal support, neurological support, sports performance, urogenital support, and weight management, as well as for men, pregnancy, seniors, teenagers, and women support. Medlab Clinical Limited was founded in 2012 and is based in Alexandria, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Medlab Clinical. Previous Next 3.3 Community Rank Outperform VotesMedlab Clinical has received 14 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMedlab Clinical has received 7 “underperform” votes. (Add your “underperform” vote.)Community SentimentMedlab Clinical has received 66.67% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Medlab Clinical and other stocks. Vote “Outperform” if you believe MDC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MDC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMedlab Clinical does not currently pay a dividend.Dividend GrowthMedlab Clinical does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medlab Clinical insiders have sold more of their company's stock than they have bought. Specifically, they have bought A$0.00 in company stock and sold A$18,620.00 in company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Medlab Clinical is -3.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Medlab Clinical is -3.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMedlab Clinical has a P/B Ratio of 3.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.66 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:MDC Previous Symbol CUSIPN/A CIKN/A Webwww.medlab.co Phone61 2 8188 0311Debt Debt-to-Equity Ratio24.76 Current Ratio3.60 Quick Ratio2.70Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$4.87 million Price / Sales10.29 Cash FlowA$0.04 per share Price / Cash Flow5.12 Book ValueA$0.05 per share Price / Book3.98Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares233,222,000Market Cap$50.14 million Next Earnings DateN/A OptionableOptionable Receive MDC News and Ratings via Email Sign-up to receive the latest news and ratings for MDC and its competitors with MarketBeat's FREE daily newsletter. Medlab Clinical (ASX:MDC) Frequently Asked Questions How has Medlab Clinical's stock been impacted by COVID-19 (Coronavirus)? Medlab Clinical's stock was trading at A$0.21 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MDC shares have increased by 2.4% and is now trading at A$0.22. View which stocks have been most impacted by Coronavirus. Has Medlab Clinical been receiving favorable news coverage? Media stories about MDC stock have trended negative on Wednesday, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Medlab Clinical earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Medlab Clinical. Who are some of Medlab Clinical's key competitors? Some companies that are related to Medlab Clinical include Enochian Biosciences (ENOB), Tiziana Life Sciences (TILS), iShares Diversified Alternatives Trust (ALT), Rafael (RFL), Pfenex (PFNX), IMV (IMV), Burcon NutraScience (BU), Neuren Pharmaceuticals (NEU), Altimmune (ALT), Resverlogix (RVX), Predictive Technology Group (PRED), CorMedix (CRMD), OncoCyte (OCX), Orgenesis (ORGS) and Matinas Biopharma (MTNB). View all competitors. What other stocks do shareholders of Medlab Clinical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medlab Clinical investors own include iSignthis (ISX), FBR (FBR), Evolve Education Group (EVO), Dacian Gold (DCN), CCP Technologies (CT1), Bingo Industries (BIN), BOD Australia (BDA), Afterpay Touch Group (APT), Alkane Resources (ALK) and Auscann Group (AC8). Who are Medlab Clinical's key executives? Medlab Clinical's management team includes the following people: Dr. Sean Michael Hall, MD, CEO & DirectorMr. Alan Dworkin, CFO & Company Sec.Dr. Luis Vitetta BSc(Hons), Grad Dip, Ph.D., Grad Dip Nutr, Director of Medical ResearchDr. David A. Rutolo, Director of ScienceMr. Paul Vilner, Director of Commercial Operations What is Medlab Clinical's stock symbol? Medlab Clinical trades on the ASX under the ticker symbol "MDC." What is Medlab Clinical's stock price today? One share of MDC stock can currently be purchased for approximately A$0.22. How big of a company is Medlab Clinical? Medlab Clinical has a market capitalization of $50.14 million and generates $4.87 million in revenue each year. What is Medlab Clinical's official website? The official website for Medlab Clinical is www.medlab.co. How can I contact Medlab Clinical? The company can be reached via phone at 61 2 8188 0311. This page was last updated on 7/8/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
